PipelineReview.com - All Products

Show Cart

All Products

Results 41 - 60 of 193

Jul 2018 CXCR4 Chemokine Receptor Antagonists – Target Pipeline List 07/2018

Jul 2018 Aryl Hydrocarbon Receptor (AHR) Agonists & Antagonists – Target Pipeline List 07/2018

Jul 2018 Novel IDO & TDO Inhibitors – Target Pipeline List 07/2018

Jul 2018 CSF-1R ( Colony Stimulating Factor 1 Receptor) Antagonists – Target Pipeline List 07/2018

Jul 2018 TGF-beta Inhibitors – Target Pipeline List 07/2018

Jul 2018 Adenosine Pathway Modulation via A2AR, CD39 & CD73 – Target Pipeline List 07/2018

Jul 2018 Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Jul 2018 GITR Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 OX40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 CD27 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 ICOS Immune Checkpoint Activators – Target Pipeline List 07/2018

Jul 2018 PD-1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 PD-L1 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 CTLA-4 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 LAG-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIM-3 Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 TIGIT Immune Checkpoint Inhibitors – Target Pipeline List 07/2018

Jul 2018 B7-H3 Immune Checkpoint Inhibitors - Target Pipeline List 07/2018

Jul 2018 CD40 Immune Checkpoint Activators – Target Pipeline List 07/2018

Jun 2018 Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing